Verastem Oncology announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company?s clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. Dr. Hayslip has more than 25 years of oncology and research and development experience across industry and academia, most recently serving as the chief medical officer at I-MAB Biopharma.

Prior to that, Dr. Hayslip was the vice president of clinical development at Nektar Therapeutics and led clinical development activities for multiple therapies while at AbbVie Oncology. Prior to joining AbbVie Oncology, Dr. Hayslip served as the chief of hematology and bone marrow transplant and the director of clinical research and data management at the University of Kentucky?s Markey Cancer Center, where he led numerous cancer research studies. Dr. Hayslip received his medical degree from Northeast Ohio Medical University and a master?s degree in clinical research from the Medical University of South Carolina.

Following his residency in internal medicine, Dr. Hayslip completed his fellowship in hematology-oncology at the Medical University of South Carolina, leading to dual board certifications in both hematology and medical oncology. He holds multiple U.S. and international patents and has published dozens of scientific papers and reviews in renowned journals including Lancet Haematology, Clinical Cancer Research, Leukemia Research, Blood, and Journal of Clinical Oncology.